Improve Research Reproducibility A Bio-protocol resource
Concise Method
tooltip

Efficacy of ADCs in mouse xenograft

VS Viswas Raja Solomon
EA Elahe Alizadeh
WB Wendy Bernhard
AM Amal Makhlouf
SH Siddesh V. Hartimath
WH Wayne Hill
AE Ayman El-Sayed
KB Kris Barreto
CG Clarence Ronald Geyer
HF Humphrey Fonge
request Request a Protocol
ask Ask a question
Favorite

When xenografts average size measured 250–350 mm3 in volume, mice were randomized into ≥ 4 mice per group and each mouse was injected intravenously via a tail vein with normal saline or three doses (~ 2.5 mg/kg) of cixutumumab, cixutumumab-PEG6-DM1-Low or cixutumumab-PEG6-DM1-High on day 0, 4, and 8. Tumor growth was monitored using a digital caliper and growth curves were established using the tumor volumes. The study was terminated when xenograft reached a volume ≥ 2000 mm3 and this was used to estimate the Kaplan Meier survival curves in the different groups. Individual body weight of mouse (every other day) was recorded during the quarantine and experimental period. At the dose selected, gross examination of organs and body weights of treated mice did not show dose limiting toxicity.

Copyright and License information: The Author(s) ©2020
Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.

Do you have any questions about this protocol?

Post your question to gather feedback from the community. We will also invite the authors of this article to respond.

post Post a Question
0 Q&A